Alternative splicing s u m m a r y Objective: Superficial Zone Protein (SZP) is expressed by the superficial zone chondrocytes and is involved in boundary lubrication of the articular cartilage surface. SZP protein expression is dependent on anatomical location and is regulated by the transforming growth factor-b (TGF-b) pathway. The hypothesis of this study was that between load-bearing, and non-load-bearing locations, of the femoral medial condyle alternative splice isoforms of SZP are different, and regulated by TGF-b1. Methods: Using reverse transcription-polymerase chain reaction (RT-PCR) we identified differentially expressed SZP alternative splicing. Using recombinant proteins of the N-terminal region produced from these isoforms, we identified differences in binding to heparin and the extracellular matrix. Results: We identified a novel splice form of SZP (isoform E), lacking exons 2e5. Differences in alternative splicing were observed between anterior load-bearing locations of the femoral medial condyle (M1) compared to the posterior non-load-bearing location (M4). TGF-b1 increased splicing out of exons 4 and 5 encoding a heparin binding domain. The minimal induction time for changes in splicing by TGF-b1 at the M1 location was 1 h, although this did change total SZP mRNA levels. Inhibition of Smad3 phosphorylation inhibited TGF-b1 induced splicing, and SZP protein expression. Recombinant proteins corresponding to isoforms upregulated by TGF-b1 had reduced binding. The SZP dimerization domain is located within exon 3. Conclusions: In conclusion, alternative splicing of SZP is regulated by TGF-b1 signaling and may regulate SZP interaction with heparin/heparan sulfate or other components in the extracellular matrix of articular cartilage by splicing out of the heparin binding domain.
Introduction
Articular cartilage is an avascular tissue with limited innate potential for repair and regeneration. The tissue provides a low friction surface for movements of the joints. Lubrication of these surfaces is critical to normal function. Products of the proteoglycan 4 (prg4) gene 1e5 have been identified as boundary lubricants of articular cartilage and stress dissipaters within the synovial joint 6 .
These protein products have been named variously as lubricin, or Superficial Zone Protein (SZP). The function of SZP and lubricin appears to be similar 3 , and these proteins are secreted by surface zone chondrocytes and synovium 1, 7 . As the tissue source used in this manuscript derives from the superficial zone of articular cartilage, SZP will be used hereafter to refer to the product of the prg4 gene.
SZP plays a key role in the normal function of synovial joints. Loss of function of SZP in human and mouse mutants displays precocious joint pathology and osteoarthritis 8 . SZP is regulated in part by cytokines involved in cartilage homeostasis 1 . Bovine prg4 gene encodes SZP and has similar exon structure to that of human, comprising 12 coding exons and a similar molecular weight (approximately 345 kD). The full length bovine product is 1195 amino acids in length compared to that of human at 1404 amino acids. This difference is due to fewer mucin repeats within exon 6, while the N-and C-terminal domains are highly homologous. Oligosaccharides attached to the mucin repeats are thought to be responsible for SZP's lubricating ability as removal of the (1e3) GaleGalNAc moieties by endo-N-acetyl-D-galactosaminidase reduced lubricating activity by 77% 9 .
SZP protein expression varies across different anatomical locations of the bovine femoral condyles with locations of higher loading having increased SZP expression 10 . This experimental model is amenable to investigate the influence of chemical and physical forces including mechanotransduction. Osteochondral plugs from the M1 (anterior medial and load bearing) and M4 (posterior medial and non-load bearing) regions of the femoral medial condyles were used. These locations have shown the greatest variability of SZP expression and mechanical loading 10, 11 . Furthermore, upregulation of SZP protein by shear was through the transforming growth factor-b (TGFb) pathway 10 . Exogenous addition of TGF-b1 was sufficient to alter the SZP expression of tissue from non-load-bearing regions (M4) to resemble that of load bearing tissue (M1) 10 . Therefore we formulated these hypotheses: (1) the greatest difference in splicing may exist between the load bearing M1 and non-load-bearing M4 locations, (2) control of alternative splicing in articular cartilage between M1 and M4 may be regulated by the TGF-b signaling pathway. We tested if recombinant isoforms had functionally different binding abilities to superficial zone articular cartilage matrix 12 . Because TGF-b splices out a potential heparin binding domain, we also tested and demonstrated binding to heparin.
Materials and methods

Materials
Articular cartilage was harvested from 1-to 3-week old bovine stifle (tibiofemoral) joints obtained from a local abattoir within 6 h of sacrifice. Dulbecco Modified Eagle's Medium (DMEM)/F12 and antibiotic solution (both from Invitrogen, Grand Island, NY), cell culture components and reagents (from Sigma, St Louis, MO or Fisher Scientific, Tustin, CA), and human recombinant TGF-b1, Activin A, B and AB (R&D Systems Inc., Minneapolis, MN) were used in this study. TGF-b1 Type 1 receptor inhibitor SB431542 and cycloheximide were from Sigma, and TGF-b1 Type 1 receptor inhibitor Type IV (Type IV), and Smad3 phosphorylation inhibitor (SIS3) were from Calbiochem (San Diego, CA).
Tissue acquisition and culture
Bovine calf stifle joints were opened using an aseptic technique, and two side-by-side osteochondral explants were harvested from M1 (anterior and load bearing) and M4 (posterior and non-load bearing) regions of the femoral medial condyles [ Fig. 1(A) ]. Hereafter, these samples will be referred to as M1 and M4 explants. A 5 mm coring reamer was used to obtain the osteochondral explants while an adjustable custom-made jig was used to trim the explants to lengths of 4 mm removing the subchondral bone. The explants were allowed to equilibrate in serum-and cytokine-free culture medium consisting of DMEM/F12, 0.2% bovine serum albumin (BSA), 1% penicillin/streptomycin, 50 mg/ml ascorbic acid 2-phosphate, and 5% CO 2 at 37 C for 24 h. The medium was replaced after the equilibration period. Subsequently, the explants were incubated in a medium supplemented with 10 ng/ml TGF-b1 or 5 mM HCL with 0.1% BSA (vehicle control) for 1 and 2 days at 37 C and 5% CO 2 . Inhibitors (SB431542, Type IV, SIS3) or cycloheximide treated samples were treated 1 h prior to addition of TGF-b1. All other wells were treated with the vehicle control [1 ml/ml dimethyl sulfoxide (DMSO) for SB431542, ethanol for Type IV, phosphate buffered saline (PBS) for SIS3 and cycloheximide]. Following treatment the top 200 mm was removed with a custom cutting jig and frozen in liquid nitrogen for RNA extraction.
Monolayer culture
Bovine calf stifle joints were obtained from a local abattoir and dissected under aseptic conditions. A Silvers miniature skin graft knife (Integra, Plainsboro, NJ) was used to obtain superficial zone samples from locations M1 and M4 of approximately 200 mm. streptomycin, 50 mg/ml ascorbic acid 2-phosphate, and 5% CO 2 at 37 C. The medium was replaced after the equilibration period with serum free DMEM/F12 and treated as described for explants 11, 13 .
RNA extraction and RT-PCR
Total RNA was harvested from superficial zone cartilage by pulverizing samples using a metal impact chamber submerged in liquid nitrogen. RNA extraction was performed using the Qiazol Lipid RNeasy Kit (Qiagen, Valencia, CA). This utilizes a modified phenoleguanidineechloroform extraction with on-membrane DNase I digestion to avoid genomic DNA contamination. cDNA was made from 5 mg of total RNA using Superscript First-Strand Synthesis System with random hexamer primers (Invitrogen, Carlsbad, CA). Primers were designed using Primer Express 1.9 (Applied Biosystems, Foster City, CA). Forward and reverse primers are: 5 0 -AACAGCCATGGAGTGGAAAATACT-3 0 located in exon 1 and 5 0 -AGTCCACTTCCATCTTCATCTATAACTG-3 0 located in exon 6, and straddle the spliced exons. The PCR reaction was optimized to ensure all isoforms produced remained within the linear range during amplification. The following amplification cycles were employed: 5 min at 95 C followed by 30 cycles of 95 C for 15 sec, 60 C for 3 min, 72 C for 3 min, and extension at 72 C for 7 min. PCR products were electrophoresed on 2% agarose gels for imaging and the bands were excised and sequenced to identify the specific isoforms [ Fig. 1 
Real-time quantitative PCR was done in triplicate on the cDNA with an ABI 7700 Sequence Detector and Sybr-Green reagents (Applied Biosystems) following the recommended protocols using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 14 Forward 5 to GAPDH levels using the formula DC t (cycle threshold) ¼ C t of GENE À C t of GAPDH. Total SZP was normalized to control and treatment using DDC t calculated as DC t of Treatment À DC t Control.
Results are presented in the form of data points representing fold change mean values AE one standard error of the mean. As differences between isoforms A and C fall at or below the 2-fold detection limit for qRT-PCR 15 , isoform differences were visualized using agarose gels. All samples were loaded at approximately equal amounts of GAPDH, which was determined using GAPDH in a qRT-PCR reaction with an endpoint within the linear range. Total amount of DNA per gel was within the linear range of the agarose gel (w300e900 ng). Gels were analyzed for densitometry in ImageJ (NIH, Bethesda, MD) isoforms were normalized as a percentage of total SZP. Similar methods for imaging splice forms have been used before 16 .
Immunoblot analysis
Equal volumes of supernatant from monolayer cultures were analyzed for secreted SZP 17 , on 3% stacking, 5% resolving sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto Immun-Blot PVDF Membrane (Bio-Rad, Hercules, CA). Monoclonal antibody against SZP, S6.79 18 (a generous gift from Dr. T. Schmid, Rush Medical College, Chicago, IL), followed by horseradish peroxidase (HRP) -conjugated goat anti-mouse IgG (Bio-Rad). Immunoblots were visualized with Supersignal West Pico chemiluminescence reagents (ThermoScientific, Waltham, MA). Immunoblot analysis of recombinant SZP isoforms was performed on 293A whole cell lysates. Equal amounts of total protein of samples were separated by reducing and nonreducing electrophoresis in 15% precast gels (Bio-Rad). Immunoblots were treated as previously described with the exception of the use of monoclonal anti-V5 antibody (Invitrogen).
Recombinant SZP isoforms
Recombinant truncated eGFP fusion proteins were produced encoding the last amino acids of exon 1 (QQASS) through the chondroitin sulfate attachment site at the beginning of exon 6 from each of the splice forms identified. In brief, these were cloned into a C-terminal egfp-c2 plasmid (Invitrogen) and a V5 tag was attached to the N-terminal end. A sixth clone representing empty green fluoroscence protein (GFP) vector was also used as a negative control. Plasmids were transfected using Lipofectamine 2000 (Invitrogen) into human embryonic kidney (HEK) 293A cells. After 48 h cell lysate was harvested.
Recombinant binding ELISA
An enzyme-linked immunosorbent assay (ELISA) was performed to determine if different isoforms bind differently to the superficial zone extracellular matrix. Superficial zone articular cartilage was removed from load-bearing regions of the lateral condyle of bovine stifle joints, frozen in liquid nitrogen and then pulverized while frozen. Extracellular matrix was extracted with 4 M guanidineeHCl, 0.05 M sodium carbonate pH 7.4 solution containing phenyl methyl sulfonyl fluoride (PMSF) and protease inhibitor cocktail (Sigma) overnight at 4 C. After extraction the solution was spun down to remove insoluble components. Extracted superficial zone extracellular matrix (10.0 mg/ml) or sodium heparin (2.0 mg/ml) was diluted in 0.05 M sodium carbonate and incubated overnight at 4 C in Maxisorp black well plates (Thermo Fisher Scientific). Extracellular matrix adsorbed plates were blocked for 1 h at room temperature with 1% BSA and washed. Recombinant truncated SZP isoforms were serially diluted in PBS and applied to ELISA plates for 1 h. Isoform binding was visualized using 1:5000 mouse anti-v5 primary antibody (Invitrogen), and 1:3000 goat anti-mouse HRP-linked secondary antibody (Bio-Rad). Signal was visualized using SuperSignal West Femto Chemiluminescence Substrate (Thermo Scientific). ELISA signal was normalized to equivalent amounts of protein run on immunoblot and analyzed for densitometry in ImageJ.
Statistical analysis
Differences in SZP mRNA expression following cytokine treatment were evaluated using a paired t-test (EXCEL Microsoft, Redmond, WA). A significance level of P < 0.05 was used to determine differences between groups, based on values from the gel densitometry.
Results
SZP alternative splicing varies by anatomical location
We mapped the alternative splice forms by anatomical location based on the previously identified mapping scheme [ Fig. 1(A) ] between the anterior load bearing M1 and posterior non-loadbearing region M4 10 . SZP isoform ratios differed between the M1 and M4 locations in freshly isolated tissue [ Fig. 1(B) ]. There are five splice forms all in-frame for exons 2 through 5. The SZP isoforms identified in the superficial zone of articular cartilage (AeE) are listed in Fig. 1C . Isoform E lacking exons 2e5 was novel. In the M1 location isoform C (splicing out of exons 4 and 5) was increased compared to isoform A (containing exons 1e5). This was designated as "full length" as this band is derived from an mRNA containing all of the exons in the alternatively spliced region and therefore all of the coding exons 1e12. This was reversed in M4 (n ¼ 7).
SZP alternative splicing is altered by TGF-b1
To investigate whether TGF-b1 regulated alternative splicing of SZP we treated explant cultures for 24 and 48 h with 10 ng/ml TGFb1. TGF-b1 was able to increase isoform C and decrease the full length isoform A in M1 and M4 explant tissues [ Fig. 2(A) ] with 24 h of treatment (n ¼ 7). Temporal differences in total SZP were also observed between the M1 and M4 locations by qRT-PCR. Explants from M1 upregulated total SZP mRNA faster then M4 explants [ Fig. 2(B) ]. A significant increase in total SZP mRNA was seen by 24 h (5.07 AE 1.3 fold n ¼ 7) and 48 h (9.5 AE 1.8 fold n ¼ 3) in M1 explants (P ¼ 0.007, 0.011). A significant increase (3.9 AE 1.4 fold) in SZP mRNA was not observed in M4 explants until 48 h after treatment (P ¼ 0.044). Significant differences were observed between 24 h timepoints of M1 and M4 explants (P ¼ 0.036), but not 48 h timepoints (P ¼ 0.26). To determine the minimal induction time of this effect, explants and monolayer cultures were treated for 1 h with 10 ng/ml TGF-b1. Total levels of SZP did not change at 1 h posttreatment in either M1 or M4 explants [ Fig. 2(B) ]. An increase in isoform C (P ¼ 0.004) was observed at 1 h post-treatment with TGFb1 at the M1 location [ Fig. 3(A) ] and a decrease in the full length isoform A (P ¼ 0.001) was also observed (n ¼ 6), indicating the M1 location is more sensitive to TGF-b1 at 1 h than the M4 location.
Addition of 40 mM cycloheximide did not affect the increase in isoform C by addition of TGF-b1 after 1 h (n ¼ 3) in M1 explants (P ¼ 0.74). [Fig. 3(B) ] This demonstrates de-novo protein synthesis is not needed for upregulation of isoform C in explants.
SZP splicing is mediated through the TGF-b Type 1 receptor kinase and Smad3
An inhibitor of TGF-b1 Type 1 receptor kinase (SB431542) was used to determine if this splicing signal was transduced through the TGF-b Type 1 receptor. Although 10 mM SB431542 was able to inhibit a decrease in isoform A by TGF-b1 after 1 h (n ¼ 4) in M1 explants [ Fig. 4(A) ], the increase in isoform C by TGF-b1 only was weak, likely due to the use of DMSO as a vehicle control. Therefore this was repeated in 48 h monolayer culture, where addition of 10 mM SB431542 was able to inhibit the increase in isoform C and decrease in isoform A by TGF-b1 (P ¼ 0.009, n ¼ 3) [Fig. 4(B) ]. This finding was then also confirmed in 48 h (P ¼ 0.019, n ¼ 3) monolayer cultures with 1 mM of Type IV inhibitor (Calbiochem) 19 , a different TGF- Furthermore, SIS3 was able to downregulate total SZP protein secreted into the media (n ¼ 3) [Fig. 4(F) ]. Addition of SIS3 downregulated both endogenous levels of SZP protein and that stimulated by TGF-b1. Differences in total SZP secreted into the media were also observed between M1 and M4 monolayer cultures although both upregulated SZP protein in response to TGF-b1 treatment.
Exons 4 and 5 increase superficial zone articular cartilage extracellular matrix binding
To identify differences in matrix binding between isoforms, truncated recombinant isoforms of SZP were produced [ Fig. 5(A) ]. Recombinant truncated isoforms of SZP bound strongest to extracellular matrix components present in guanidine extracts of superficial zone articular cartilage when exons 4 and 5 were present. Binding of isoform A (exons 2e5) and isoform B (exons 3e5) was stronger then that of isoforms with exons 4 and 5 spliced out (CeE) which had weaker binding observed [ Fig. 5(B) ]. Levels of binding of isoforms C and D were similar to that of isoform E, which contained only a partial exon 6 and the C-terminus. The level of signal at the no isoform control is similar to isoforms CeE at all concentrations. Therefore this represents background signal and indicates a lack of binding for isoforms CeE. As exon 4 encodes a heparin binding domain, we also tested if this was competent to bind to sodium heparin. Binding of isoforms A, B with exons 4 and 5 present was strongest, with weaker binding of forms lacking exons 4 and 5 (CeE) [ Fig. 5(B) ].
Exon 3 is a potential dimerization domain
SZP has been reported to exist in both monomeric and dimeric forms 12,21 through a disulfide bond within the N-terminal domains. To determine the dimerization domain of SZP, the recombinant truncated SZP isoforms were run on SDS-PAGE under reducing and non-reducing conditions. Bands of the correct size for dimers were observed for all forms except E (corresponding to isoform E), which lacks exons 2 through 5 [ Fig 
Discussion
Alternative splicing of RNA permits the production of distinct protein isoforms from a single gene. Several splice forms of SZP have been identified in normal cartilage involving exons 2, 4, and 5 1, 22 . SZP alternative splicing in tendon has been shown to vary based on anatomical location corresponding to load 23 . Shear loading induced upregulation of SZP protein through the TGFb Type 1 receptor kinase 10 . Previous work has demonstrated SZP protein expression increases with dynamic loading, and that this alters the ratio of the protein product sizes found when compared to unloaded controls 24 . It is noteworthy that alternative splicing of RNA in cartilage explant cultures is different in the various anatomical sites such as load bearing M1 compared to the non-load-bearing M4 site. In the M1 site splicing out of exons 4 and 5 is upregulated. Treatment of the non-load-bearing site M4 explant with TGF-b1 alters the alternative splicing to resemble load bearing M1.
The rapidity of the splicing response (1 h treatment) to TGF-b1 treatment in the absence of protein synthesis in cartilage explant cultures is remarkable. Inhibition of Smad3 phosphorylation demonstrates that phosphorylation of Smad2 is not sufficient to regulate splicing out of exons 4 and 5 in 1 h M1 explants or 48 h monolayer culture. However, this action could be indirect due to blocking of TGF-b induced upregulation of TGF-b signaling 25e27 . Disulfide bonded dimerization of SZP has been identified to occur within the N-terminal region of the molecule 12 , localized to a region of exons 2 through 5. Although not definitive, the presence of dimers of the apparent correct molecular size lends support to the Somatomedin B domain encoded within exon 3 as being the likely dimerization domain, it remains possible that exon 2 which contains a similar Somatomedin B domain is also capable of dimerizing. This remains unlikely to exist in nature though, as exon 3 is present in all alternative splice forms identified except E, and no isoforms were identified containing exon 2 but not 3. Loss of exon 3 appears to be relatively rare, as isoform E appeared to be of low abundance.
The functional differences between the alternatively spliced RNA forms are critical. The SZP C-terminal domain is critical for binding to extracellular matrix 21, 28 and recently a model supporting N-terminal domain binding abilities has been described 12, 29 .
Although the binding conditions are quite different, this is puzzling in the light of, previous recombinant work 21, 28 which showed minimal binding of the N-terminal domain in recombinant proteins to intact cartilage superficial zone. Recent work has proposed that SZP may exist as a horseshoe configuration with both N and C terminals bound to the extracellular matrix, leaving the highly glycosylated central mucin domain exposed for interactions during boundary lubrication 12 .
Here we investigated the role of the Nterminal domains to bind matrix components, as potentially modulated by splicing. Compared to the isoforms containing exons 4 and 5 (A and B), those isoforms lacking exons 4 and 5 resulted in reduced matrix or heparin binding. However, as these matrix components were guanidine extracted, this may not represent native tissue conditions. This does suggest that SZP lacking exons 4 and 5, as upregulated by TGF-b, may have different binding capabilities.
Splicing may serve as a mechanism to control the ratio of SZP bound to the articular cartilage compared to SZP free floating in the synovial fluid, which can have consequences on lubrication 30 .
Therefore, in vivo conditions (changes in biochemical homeostasis or mechanical loading) might change binding ability of SZP to matrix, and subsequently lubrication of the joint. Furthermore, mechanistically this suggests that Smad3 may regulate both SZP protein concentration and the specific isoform produced through alternative splicing. Growth factor regulation of splicing, especially that of quick changes in splicing due to phosphorylation of factors controlling splicing has been described in other systems 31 .
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